Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.66)
# 3,090
Out of 4,784 analysts
67
Total ratings
40.91%
Success rate
-5.22%
Average return
Main Sectors:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $54.80 | +20.44% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $39.86 | -44.81% | 8 | Nov 5, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $77 → $74 | $131.81 | -43.86% | 5 | Aug 8, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $3.01 | +398.34% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $17.05 | +169.79% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $10.38 | +73.41% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.65 | +203.03% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.32 | +144.36% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $33.19 | -15.64% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $47.41 | +9.68% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $64 | $2.12 | +2,918.87% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $1.22 | +1,785.25% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.59 | +1,220.75% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $2.92 | +379.45% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $28.98 | -72.39% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.31 | +5,145.90% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $54.80
Upside: +20.44%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $39.86
Upside: -44.81%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $77 → $74
Current: $131.81
Upside: -43.86%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $3.01
Upside: +398.34%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $17.05
Upside: +169.79%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $10.38
Upside: +73.41%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.65
Upside: +203.03%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.32
Upside: +144.36%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $33.19
Upside: -15.64%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $47.41
Upside: +9.68%
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.12
Upside: +2,918.87%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $1.22
Upside: +1,785.25%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.59
Upside: +1,220.75%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $2.92
Upside: +379.45%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $28.98
Upside: -72.39%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.31
Upside: +5,145.90%